MX2021005386A - Fragmentos de peptidos para tratamiento de diabetes. - Google Patents

Fragmentos de peptidos para tratamiento de diabetes.

Info

Publication number
MX2021005386A
MX2021005386A MX2021005386A MX2021005386A MX2021005386A MX 2021005386 A MX2021005386 A MX 2021005386A MX 2021005386 A MX2021005386 A MX 2021005386A MX 2021005386 A MX2021005386 A MX 2021005386A MX 2021005386 A MX2021005386 A MX 2021005386A
Authority
MX
Mexico
Prior art keywords
treatment
peptide fragments
diabetes
concerns
endocrine
Prior art date
Application number
MX2021005386A
Other languages
English (en)
Spanish (es)
Inventor
Jan Alenfall
Pontus Dunér
Maria Ekblad
Original Assignee
Follicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum Ab filed Critical Follicum Ab
Publication of MX2021005386A publication Critical patent/MX2021005386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021005386A 2018-11-07 2019-11-07 Fragmentos de peptidos para tratamiento de diabetes. MX2021005386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2021005386A true MX2021005386A (es) 2021-07-06

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005386A MX2021005386A (es) 2018-11-07 2019-11-07 Fragmentos de peptidos para tratamiento de diabetes.

Country Status (13)

Country Link
US (2) US20220002343A1 (https=)
EP (1) EP3876970A1 (https=)
JP (1) JP7553115B2 (https=)
KR (1) KR20210088583A (https=)
CN (1) CN113164548A (https=)
AU (1) AU2019374981A1 (https=)
BR (1) BR112021008888A2 (https=)
CA (1) CA3116612A1 (https=)
IL (1) IL282519A (https=)
MX (1) MX2021005386A (https=)
SG (1) SG11202104276YA (https=)
WO (1) WO2020094797A1 (https=)
ZA (1) ZA202102572B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
JP2025516717A (ja) * 2022-05-13 2025-05-30 コーギン ファーマ エービー 血管新生を誘発する薬剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505750A (ja) * 1994-09-16 1998-06-09 ザ スクリップス リサーチ インスティテュート 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
WO2004015390A2 (en) 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
US9044438B2 (en) * 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
CA3061935A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Also Published As

Publication number Publication date
AU2019374981A1 (en) 2021-05-27
SG11202104276YA (en) 2021-05-28
BR112021008888A2 (pt) 2021-08-17
KR20210088583A (ko) 2021-07-14
ZA202102572B (en) 2022-10-26
US20240327459A1 (en) 2024-10-03
CA3116612A1 (en) 2020-05-14
IL282519A (en) 2021-06-30
US20220002343A1 (en) 2022-01-06
WO2020094797A1 (en) 2020-05-14
JP2022516400A (ja) 2022-02-28
EP3876970A1 (en) 2021-09-15
JP7553115B2 (ja) 2024-09-18
CN113164548A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
CA193736S (en) Skin massager
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
MY209489A (en) Antibody against human il-4ra and use thereof
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
MX2019008197A (es) Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.
MX380322B (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1).
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX2018010640A (es) Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
HK1220383A1 (zh) 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
AU201815816S (en) Inhaler
ZA202103259B (en) Modified cas9 protein, and use thereof
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
NZ757105A (en) Methods of treating and/or preventing actinic keratosis
AU201810114S (en) A footbed for a shoe
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof